The ASCO Annual Meeting, American Society of Oncology, took place June 1st to 5 in the US. That is one of the most important congresses on oncology.
Doctors, health professionals and patient advocates met to discuss the advances in the field, research and new knowledge about cancer.
Among the studies presented at the Congress, the most relevant for breast cancer patients were: the time of treatment with Trastuzumabe; TailorX and genetic testing; prophylactic radiotherapy and immunotherapy.
Trastuzumab
Researchers at the University of Cambridge and Warwick Clinical Trials conducted a study with 4,000 women at the early stage of HER2 Positive breast cancer.
It was verified that when the treatment with Trastuzumab, in 6 months, different from the standard of 12 months, the patients have the same cure rate and the side effects are mitigated.
To learn more details of this study, click here.
TailorX
This research had as a source of study 10,000 women in the early stage of hormone receptor positive breast cancer.
From the application of a genetic test, the Oncotype DX® Breast Recurrence Score, were separated the patients who had high risk and low risk of cancer recurrence.
Low risk women were divided into two groups: one group received chemotherapy and hormone therapy and another received only hormone therapy. After 7.5 years of follow-up, patients in both groups presented similar profiles. This means that chemotherapy was not determinant in the treatment of these patients.
Want to read more about this study? Click here.
ASCO
It is a North American association that promotes this meeting every year. The topics, new drugs and procedures presented at ASCO are usually very important for medical practice. They directly affect the patient's reality. Therefore, the importance of this meeting.
To know more about ASCO and the papers presented, visit: www.asco.org.